# PI-005 — Clinical AI Report

## Clinical Artificial Intelligence Services

**Version:** 2.1.0
**Date:** July 2026

---

## 1. Drug Interaction Checking

### 1.1 Overview

The Drug Interaction Checker analyzes all active prescriptions for potential adverse drug reactions (ADRs) before a prescription is finalized.

### 1.2 Interaction Types Detected

| Type | Severity | Example | Action Required |
|------|----------|---------|----------------|
| Contraindicated | Critical | Warfarin + Aspirin | Block prescription, alert prescriber |
| Major | High | Metformin + Iodinated contrast | Require pharmacist override |
| Moderate | Medium | ACE inhibitor + Potassium | Warning with monitoring suggestion |
| Minor | Low | Antacid + Tetracycline | Informational note |

### 1.3 Data Sources

- **DrugBank** (licensed): 14,000+ drugs, 450,000+ interaction pairs
- **Iraqi National Formulary**: Country-specific approved drugs and guidelines
- **WHO Essential Medicines List**: Cross-reference
- **Clinical trials database**: Adverse event reports

### 1.4 Alert Workflow

```
Prescription Created
    ▼
Drug Interaction Checker
    ├── Check all active medications (current + new)
    ├── Check OTC medications (patient-reported)
    ├── Check allergies (patient record)
    ├── Check lab values (renal/hepatic function)
    ▼
No Interaction Found → Prescription proceeds
Interaction Found:
    ├── Critical: Block with explanation
    ├── Major: Alert with alternative suggestion
    ├── Moderate: Warning with monitoring recommendation
    └── Minor: Informational note (collapsible)
```

### 1.5 Performance

| Metric | Value |
|--------|-------|
| Average check time | 350ms |
| Interaction coverage | 98.5% of known interactions |
| False positive rate | 2.1% |
| Sensitivity | 99.2% |
| Specificity | 97.8% |

---

## 2. Critical Result Detection

### 2.1 Detection Categories

| Category | Examples | Notification Within |
|----------|----------|-------------------|
| Panic values | Critical low/high (e.g., glucose < 40 mg/dL) | Immediate (5 min) |
| Critical trends | Rapid change in serial results | 15 minutes |
| Infectious disease | Positive TB, hepatitis, HIV markers | 30 minutes |
| Tumor markers | Significant elevation | 60 minutes |
| Drug levels | Toxic range (e.g., digoxin > 2.0 ng/mL) | Immediate (5 min) |

### 2.2 Iraqi National Reference Ranges

All critical thresholds are configured against Iraqi Ministry of Health reference ranges, which account for:
- Regional demographic variations
- Local population genetics
- Altitude and environmental factors
- Age-adjusted ranges (validated for Iraqi population)

### 2.3 Alert Routing

```
Critical Result Detected
    ▼
Severity Assessment
    ├── PANIC: SMS + Phone call to ordering physician
    ├── CRITICAL: Push notification to Doctor app + Lab app
    ├── WARNING: In-app alert + email summary
    └── INFO: Added to patient timeline
    ▼
Escalation if unacknowledged:
    ├── 5 min: First notification
    ├── 15 min: Escalation to department head
    ├── 30 min: Escalation to hospital administration
    └── 60 min: Escalation to Ministry of Health
    ▼
Acknowledged → Recorded in audit log with timestamp + responder
```

---

## 3. Clinical Pathways

### 3.1 Pathway Library

| Specialty | Pathways | Evidence Source |
|-----------|----------|----------------|
| Internal Medicine | 45 | ACP + Iraqi MoH guidelines |
| Cardiology | 30 | ACC/AHA + ESC + Iraqi protocols |
| Endocrinology | 25 | ADA + Iraqi Diabetes Association |
| Infectious Disease | 35 | WHO + Iraqi CDC |
| Oncology | 20 | NCCN + Iraqi Cancer Board |
| Pediatrics | 40 | AAP + Iraqi Pediatric Society |
| Obstetrics/Gynecology | 28 | ACOG + Iraqi MoH maternal health |
| Emergency Medicine | 50 | ACEP + Iraqi emergency protocols |

### 3.2 Pathway Execution

```
Patient Diagnosis (ICD-10 code assigned)
    ▼
Clinical Pathway Engine
    ├── Retrieve pathway matching diagnosis
    ├── Customize for patient demographics (age, gender, comorbidities)
    ├── Check available lab results
    ├── Suggest next steps with evidence level
    ▼
Present to Clinician:
    └── Recommended actions (with evidence grades A-D)
    └── Alternative options
    └── Relevant clinical trials
    └── Expected outcomes
    ▼
Clinician Decision:
    ├── Accept suggestion → Action recorded
    ├── Modify suggestion → Reason documented
    └── Reject suggestion → Alternative documented
```

### 3.3 Compliance Tracking

| Metric | Target | Current |
|--------|--------|---------|
| Pathway adherence | > 80% | 76% |
| Deviation documentation | 100% | 98% |
| Evidence-based ordering | > 90% | 87% |
| Unnecessary test reduction | > 20% | 23% |

---

## 4. Decision Support Workflow

### 4.1 Support Types

| Type | Trigger | Information Provided |
|------|---------|---------------------|
| Diagnostic | During diagnosis entry | Differential diagnosis, relevant tests, clinical criteria |
| Therapeutic | During order creation | Drug interactions, dosing, alternatives |
| Preventive | Patient encounter | Screening reminders, vaccination schedule |
| Prognostic | Result review | Risk scores, outcome predictions, follow-up schedule |

### 4.2 CDS (Clinical Decision Support) Rules

The system implements 250+ CDS rules covering:
- Drug-drug interactions (150 rules)
- Drug-allergy checking (40 rules)
- Drug-disease contraindications (30 rules)
- Duplicate therapy detection (15 rules)
- Dosing and adjustment (renal/hepatic) (20 rules)
- Guideline-based recommendations (50 rules)

---

## 5. Human-in-the-Loop Approval

### 5.1 Approval Matrix

| Decision Type | AI Role | Human Role | Override |
|---------------|---------|------------|----------|
| Drug interaction (critical) | Alert + block | Pharmacist review | Senior pharmacist |
| Drug interaction (major) | Alert + suggest | Pharmacist review | Any pharmacist |
| Critical result | Detect + notify | Clinician acknowledges | Department head |
| Clinical pathway | Suggest | Physician decides | N/A |
| Diagnosis suggestion | Suggest | Physician confirms | N/A |
| Risk prediction | Score | Clinician interprets | N/A |
| Treatment plan | Options | Shared decision-making | N/A |

### 5.2 Approval Queue

```
AI Decision → Human Review Queue
    ├── Priority: Based on severity (critical → high → medium)
    ├── Assignment: Round-robin to available qualified staff
    ├── SLA: 5 min (critical), 15 min (high), 60 min (medium)
    ├── Escalation: Unacknowledged → next tier
    └── Audit: Full record of decision + reviewer
```

---

## 6. Clinical Safety Measures

### 6.1 Safety Barriers

| Barrier | Description | Effectiveness |
|---------|-------------|---------------|
| Input validation | All AI inputs validated against schema (zod) | 100% |
| Output guardrails | AI outputs checked against allowed ranges | 99.9% |
| Confidence threshold | Predictions < 70% confidence flagged for review | 100% |
| Human review gate | Critical decisions always require human approval | 100% |
| A/B testing | New models run parallel with live for 30 days | 100% |
| Fallback protocol | If AI unavailable, system falls back to manual | 100% |

### 6.2 Safety Metrics

| Metric | Target | Current |
|--------|--------|---------|
| False negative (missed ADR) | 0 | 0 |
| False positive (unnecessary alert) | < 5% | 2.1% |
| Alert acknowledgment rate | > 95% | 97.3% |
| Time to critical alert acknowledgment | < 5 min | 3.2 min |
| Human override rate | < 10% | 6.8% |
| Clinical decision improvement | > 15% | 18.5% |

### 6.3 Regulatory Compliance

| Standard | Status | Evidence |
|----------|--------|----------|
| Iraqi MoH Clinical AI Guidelines | ✅ Compliant | Approval workflow documentation |
| WHO Digital Health Guidelines | ✅ Compliant | Safety barrier documentation |
| HIPAA Security Rule (aligned) | ✅ Compliant | Audit trail + encryption |
| IEC 62304 (Software Medical Devices) | ⚠️ Partial | Gap analysis underway |
| ISO 13485 (Quality Management) | ⚠️ Partial | QMS implementation Q3 2026 |

---

## 7. Model Inventory

| Model Name | Version | Task | Status | Accuracy | Recall |
|------------|---------|------|--------|----------|--------|
| gula-drug-interaction-v1 | 1.2.0 | Drug interaction detection | Production | 99.2% | 98.7% |
| gula-critical-result-v2 | 2.1.0 | Critical value detection | Production | 99.8% | 99.5% |
| gula-clinical-pathway-v1 | 1.0.0 | Pathway suggestion | Production | 94.3% | 92.1% |
| gula-bed-occupancy-v1 | 1.0.0 | Bed prediction | Staging | 91.2% | 89.8% |
| gula-disease-forecast-v1 | 1.0.0 | Disease forecasting | Staging | 87.5% | 85.3% |
| gula-readmission-risk-v1 | 1.0.0 | Readmission prediction | Development | 83.1% | 81.2% |
| gula-health-assistant-v1 | 1.0.0 | Citizen health Q&A | Staging | 92.4% | 90.6% |
| gula-symptom-checker-v1 | 1.0.0 | Symptom triage | Development | 86.7% | 84.5% |
